Inhibition of hemangioma development in a syngeneic mouse model correlates with bcl-2 suppression and the inhibition of Akt kinase activity

Angiogenesis

Volumn 15, Issue 1, 2012, Pages 131-139

  Mabeta, Peace ^a   Pepper, Michael S ^a,b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Akt; Bcl 2; Bleomycin; Caspase; Hemangioma

Indexed keywords

BLEOMYCIN; CASPASE; EOSIN; HEMATOXYLIN; PROTEIN BCL 2; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMANGIOMA; HISTOLOGY; LOADING DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; CELL TRANSFORMATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ASSAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; STAINING;

ANIMALS; BLEOMYCIN; CASPASES; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ASSAYS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEMANGIOMA; MICE; MICE, INBRED C57BL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 84861558883     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9248-7     Document Type: Article

References (41)

1. Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstruct Surg 69:412-422
2. Bruckner AL, Frieden IJ (2003) Hemangiomas of infancy. J Am Acad Dermatol 48:477-493
3. Bauland CG, van Steensel MA, Steijlen PM, Rieu PN, Spauwen PH (2006) The pathogenesis of hemangiomas: a review. Plast Reconstruct Surg 117:29e-35e
4. Blei F (2005) Basic science and clinical aspects of vascular anomalies. Curr Opin Pediatr 17:501-509
5. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357-2364
6. Zhang G, Yi C, Li X, Liang Z, Wang R, Liu D et al (2008) Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases. Med Hypotheses 70:815-818
7. Enjolras O, Mulliken JB (1993) The current management of vascular birthmarks. Pediatr Dermatol 10:311-313
8. Barlow CF, Priebe CJ, Mulliken JB, Barnes PD, Mac Donald D, Folkman J et al (1998) Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 132:527-530
9. Grimal I, Duveau E, Enjolras O, Verret JL, Ginies JL (2000) Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants. Arch Pediatrie 7:163-167
10. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E et al (2004) Traitement par vincristine des hémangiomes graves du nourrisson. Arch Pédiatrie 11:99-107
11. Zvulonov A, Metzer A (2002) Hemangiomas and vascular malformations: unapproved treatments. Clin Dermatol 20:660-667
12. Sarihan H, Mocan H, Yildiz K, Abes M, Akyazici R (1997) A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 7:158-162
13. Kullendorff CM (1997) Efficacy of bleomycin treatment for symptomatic hemangiomas in children. Pediatr Surg Int 12:526-528
14. Muir T, Kirsten M, Fourie P et al (2004) Intralesional bleomycin injection (IBI) for hemangiomas and congenital vascular malformations. J Pediatr Surg 39:1735-1736
15. Pienaar C, Graham R, Geldenhuys S, Hudson DA (2006) Intralesional bleomycin for the treatment of hemangiomas. Plast Reconstr Surg 117:221-226
16. Mabeta P, Davis PF (2008) The mechanism of bleomycin in inducing hemangioma regression. S Afr Med J 98:538-539
17. Mabeta P, Pepper MS (2009) A comparative study on the antiangiogenic effects of DNA damaging and cytoskeletal-disrupting agents. Angiogenesis 12:81-90
18. Liekens S, Verbeken E, Vandeputte M, De Clercq E, Neyts J (1999) A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470 Cancer Res 59:2376-2383
19. Bautch VL, Toda S, Hassell JA et al (1987) Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene. Cell 51:529-538
20. Sabapathy KT, Pepper MS, Kiefer F et al (1997) Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J Cell Biol 137:953-963
21. Dubois-Stringfellw NK, Olpack-Martindale L, Bautch VL, Azizkhan RG (1994) Mice with hemangiomas induced by transgenic endothelial cells. Am J Pathol 144:796-806
22. Pepper MS, Tacchini-Cottier F, Sabapathy TK et al (1997) Tumor angiogenesis. Endothelial cells transformed by polyoma virus middle T oncogene: a model for hemangiomas and other vascular tumors. In: Bicknell R, Lewis CE, Ferrara N (eds) Tumor angiogenesis. Oxford University Press, Oxford, pp 309-331
23. Kiefer M, Courtneidge SA, Wagner EF (1994) Oncogenic properties of the middle T antigens of polyoma viruses. Adv Cancer Res 64:125-157
24. Kaplan DR, Pallas DC, Morgan W et al (1989) Mechanisms of transformation by polyoma virus middle T antigen. Biochim Biophys Acta 948:345-364
25. Dubois NA, Kolpack LC, Wang R et al (1991) Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas. Exp Cell Res 196:302-313
26. Taraboletti G, Belotti D, Dejana E, Mantovani A, Giavazzi R (1993) Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene. Cancer Res 53:3812-3816
27. Mabeta P, Pepper MS (2011) Hemangiomas-current therapeutic strategies. Int J Dev Biol 55:431-437
28. Williams RL, Risau W, Zerwes H-G et al (1989) Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell 57:1053-1063
29. Cheng J, Slavin RE, Gallagher JA, Zhu G, Biehl TR, Swanstrom LL, Hansen PD (2004) Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases. J Hepato- biliary Pan 11:164-170
30. Perrone G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetrani A, Rabitti C (2004) Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 208:227-234
31. Kumar P, Ning Y, Polverini PJ (2008) Endothelial cells expressing Bcl-2 promote tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest 88:740-749
32. Maillux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B (2001) Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 80:442-449
33. Fontanini G, Boldrini L, Vignati S, Chinè S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G (1998) Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)- mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 34:718-723
34. Burlacu A (2003) Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7:249-257
35. Tezel G, Wax MB (1999) Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci 40:2660-2667
36. Dawson S-J, Makretsov N, Blows FM et al (2010) BCL2 in breast cancer: a favorable prognostic marker across molecular subtypes and independent of adjuvant therapy. Br J Cancer 103:668-675
37. Ferenc P, Solár P, Kleban J, Mikeš J, Fedoročko P (2010) Downregulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. J Photoch Photobio B 98:25-34
38. Moon D-O, Park S-Y, Choi Y-H, Kim ND, Chan Lee C, Kim G-Y (2008) Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells. Toxicon 51:112-120
39. Li B, Xu W, Luo C, Gozal D, Liu R (2003) VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1- mediated motor neuron cell death. Mol Brain Res 111:155-164
40. Zhao J, Miao J, Zhao B, Zhang S, Yin D (2006) Suppressing Akt phosphorylation and activating Fas by safrole oxide inhibited angiogenesis and induced vascular endothelial cell apoptosis in the presence of fibroblast growth factor-2 and serum. Int J Biochem Cell Biol 38:1603-1613
41. Enjolras O, Wassef M, Mazoyer E et al (1997) Infants with Kasabach-Merritt syndrome do not have 'true' hemangiomas. J Pediatr 130:631-640